Jazz Pharmaceuticals
JAZZ
373 hedge funds and large institutions have $9.87B invested in Jazz Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 51 funds opening new positions, 121 increasing their positions, 146 reducing their positions, and 30 closing their positions.
70% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 30
9% more capital invested
Capital invested by funds: $9.08B → $9.87B (+$788M)
5% more funds holding
Funds holding: 354 → 373 (+19)
17% less repeat investments, than reductions
Existing positions increased: 121 | Existing positions reduced: 146
28% less funds holding in top 10
Funds holding in top 10: 18 → 13 (-5)
52% less call options, than puts
Call options by funds: $54M | Put options by funds: $113M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$272M |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$261M |
| 3 |
PC
PointState Capital
New York
|
+$76.6M |
| 4 |
BG
BlackRock Group
London,
United Kingdom
|
+$71.1M |
| 5 |
NC
Nicholas Company
Milwaukee,
Wisconsin
|
+$60.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
-$68.1M |
| 2 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$65.5M |
| 3 |
HM
HealthCor Management
New York
|
-$56.2M |
| 4 |
LPC
Lone Pine Capital
Greenwich,
Connecticut
|
-$45.1M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$27.3M |
JAZZ Hedge Fund Activity: Q2 2015 in Review
373 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q2 2015, worth a combined $9.87B — up 8.7% from $9.08B a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new JAZZ positions and 30 closed out — a net gain of 21 holders — while 121 added to existing stakes and 146 trimmed.
The largest buyer was BlackRock Fund Advisors, opening a new position worth an estimated $272M. The largest seller was Wells Fargo, cutting an estimated $68.1M.
- 373 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q2 2015, up from 354 in Q1 2015.
- Funds reported $9.87B of Jazz Pharmaceuticals stock for Q2 2015, up 8.7% quarter-over-quarter.
- 51 funds opened new Jazz Pharmaceuticals positions in Q2 2015 and 30 closed out, a net change of +21 holders.
- The largest Jazz Pharmaceuticals buyer in Q2 2015 was BlackRock Fund Advisors, an estimated $272M added.
- The largest Jazz Pharmaceuticals seller in Q2 2015 was Wells Fargo, an estimated $68.1M sold.
Based on aggregated 13F filings for Q2 2015.